PD06.09. Second-Line Treatment Efficacy in Functional Heartburn Based on HRM and MII-pH Evaluation
Diseases of the Esophagus · 22.08.2026 · 39 (Supplement_1)
DOI: 10.1093/dote/doag077.121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 22.08.2026. Verfasst von Hiromi Arakawa und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Topic Benign Disease: Gastro-Esophageal Reflux and Hiatal Hernia Background Functional heartburn (FH) accounts for approximately half of patients with proton pump inhibitor (PPI)- or vonoprazan-refractory non-erosive reflux symptoms. However, the clinical characteristics of FH and the efficacy of second-line therapies remain incompletely understood. We evaluated patient characteristics and treatment outcomes following physiological evaluation.
Methods
Between September 2013 and December 2025, we retrospectively reviewed patients with PPI- or vonoprazan-refractory heartburn who underwent high-resolution manometry (HRM) and multichannel intraluminal impedance–pH (MII-pH) monitoring after discontinuation of acid-suppressive therapy at our institution. FH was diagnosed according to the updated Lyon Consensus 2.0 criteria. Clinical characteristics were compared between FH and true NERD. Symptom severity was assessed using the Frequency Scale for the Symptoms of GERD (FSSG). We evaluated comorbid conditions diagnosed after FH identification and analyzed the type and efficacy of second-line therapies. Treatment response was defined as a ≥50% reduction in FSSG score.
Results
Among 303 MII-pH studies, 125 patients were evaluated off acid-suppressive therapy for refractory heartburn, and 47 (38%) were diagnosed with FH. Compared with true NERD, FH patients were more often female (58.4% vs. 29.6%, p=0.008), younger (59.0 vs. 69.0 years, p=0.03), and had lower BMI (21.3 vs. 23.7, p<0.001). The GSRS indigestion score was higher in FH (10.0 vs. 8.5, p=0.047). Fifteen patients were subsequently diagnosed with psychiatric, cardiovascular, otolaryngological, or orthopedic conditions, with symptom improvement following appropriate treatment. Among 15 patients receiving second-line therapy with evaluable FSSG scores, 10 (66.7%) achieved ≥50% symptom improvement. SSRIs significantly reduced median FSSG scores from 20 (17.5–26.0) to 7.0 (4.0–10.5) (p=0.018). Acid-suppressive therapy was discontinued in 61.7% of FH patients.
Conclusion
FH demonstrated distinct clinical characteristics compared with true NERD. Following comprehensive physiological evaluation using HRM and MII-pH, second-line therapies—particularly SSRIs—were associated with substantial symptom improvement. Physiologically guided, individualized management may improve outcomes in patients with FH.
Zitieren
APA
Arakawa, H., Matsumura, T., Ozaki, T., Iwasaki, M., Sonoda, M., & Kato, J. (2026). PD06.09. Second-Line Treatment Efficacy in Functional Heartburn Based on HRM and MII-pH Evaluation. Diseases of the Esophagus, 39(Supplement_1). https://doi.org/10.1093/dote/doag077.121
Vancouver
Arakawa H, Matsumura T, Ozaki T, Iwasaki M, Sonoda M, Kato J. PD06.09. Second-Line Treatment Efficacy in Functional Heartburn Based on HRM and MII-pH Evaluation. Diseases of the Esophagus. 2026;39(Supplement_1). doi:10.1093/dote/doag077.121
BibTeX
@article{Arakawa2026,
author = {Arakawa, Hiromi and Matsumura, Tomoaki and Ozaki, Tomomi and Iwasaki, Miyuki and Sonoda, Michiko and Kato, Jun},
title = {PD06.09. Second-Line Treatment Efficacy in Functional Heartburn Based on HRM and MII-pH Evaluation},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {Supplement_1},
doi = {10.1093/dote/doag077.121}
}
EUVIMED